Abstract: The invention relates to chimeric AAV capsids targeted to the central nervous system, virus vectors comprising the same, and methods of using the vectors to target the central nervous system. The invention further relates to chimeric AAV capsids targeted to oligodendrocytes, virus vectors comprising the same, and methods of using the vectors to target oligodendrocytes.

Abstract: Disclosed herein are methods and compositions for gene therapy, in particular, methods and compositions related to alterations in a capsid protein sequence for altering permissiveness of a promoter within a cell when the promoter and the capsid protein are present within the cell and the capsid protein and the promoter are in the context of a recombinant adeno-associated virus (AAV) particle.

Abstract: The invention relates to chimeric AAV capsids targeted to the central nervous system, virus vectors comprising the same, and methods of using the vectors to target the central nervous system. The invention further relates to chimeric AAV capsids targeted to oligodendrocytes, virus vectors comprising the same, and methods of using the vectors to target oligodendrocytes.

Abstract: The invention relates to products and methods for transdifferentiating oligodendrocytes and/or oligodendrocyte precursor cells to neurons. The invention further relates to methods of treating central nervous system disorders and conditions.

Abstract: The invention relates to chimeric AAV capsids targeted to the central nervous system, virus vectors comprising the same, and methods of using the vectors to target the central nervous system. The invention further relates to chimeric AAV capsids targeted to oligodendrocytes, virus vectors comprising the same, and methods of using the vectors to target oligodendrocytes.

Abstract: The invention relates to chimeric AAV capsids targeted to the central nervous system, virus vectors comprising the same, and methods of using the vectors to target the central nervous system. The invention further relates to chimeric AAV capsids targeted to oligodendrocytes, virus vectors comprising the same, and methods of using the vectors to target oligodendrocytes.

Abstract: The invention relates to chimeric AAV capsids targeted to the central nervous system, virus vectors comprising the same, and methods of using the vectors to target the central nervous system. The invention further relates to chimeric AAV capsids targeted to oligodendrocytes, virus vectors comprising the same, and methods of using the vectors to target oligodendrocytes.

Abstract: The invention relates to chimeric AAV capsids targeted to the central nervous system, virus vectors comprising the same, and methods of using the vectors to target the central nervous system. The invention further relates to chimeric AAV capsids targeted to oligodendrocytes, virus vectors comprising the same, and methods of using the vectors to target oligodendrocytes.

Abstract: The invention relates to chimeric AAV capsids targeted to oligodendrocytes, virus vectors comprising the same, and methods of using the vectors to target oligodendrocytes.

Abstract: The invention relates to products and methods for transdifferentiating oligodendrocytes and/or oligodendrocyte precursor cells to neurons. The invention further relates to methods of treating central nervous system disorders and conditions.

Abstract: The invention relates to chimeric AAV capsids targeted to the central nervous system, virus vectors comprising the same, and methods of using the vectors to target the central nervous system. The invention further relates to chimeric AAV capsids targeted to oligodendrocytes, virus vectors comprising the same, and methods of using the vectors to target oligodendrocytes.

Abstract: The invention relates to chimeric AAV capsids targeted to oligodendrocytes, virus vectors comprising the same, and methods of using the vectors to target oligodendrocytes.

Abstract: The invention relates to chimeric AAV capsids targeted to oligodendrocytes, nucleic acids encoding the capsids, virus vectors and particles comprising the same, methods of producing the vectors, and methods of using the vectors to target oligodendrocytes. The invention further relates to methods of treating a disorder associated with oligodendrocyte dysfunction using the vectors.

Abstract: The invention relates to chimeric AAV capsids targeted to oligodendrocytes, virus vectors comprising the same, and methods of using the vectors to target oligodendrocytes.

Abstract: This invention provides detergent compositions, particularly liquid compositions, utilizing one or more polycarboxylates as builders, or as anti-redeposition agents, wherein the polycarboxylates are novel polymers comprising repeating units of the structure: ##STR1## wherein m is a mole fraction from 0.70 to 0.95; n is a mole fraction from 0.05 to 0.30; A is derived from at least one ethylenically unsaturated carboxylic acid monomer; B is derived from at least one ethylenically unsaturated carboxylic acid monomer and B is not A; and C is: ##STR2## wherein X is --H, ##STR3## or a combination thereof, R.sup.1 is --H, --CH.sub.3, or --(CH.sub.2).sub.q CH.sub.3, or a combination thereof, and q is 1-5; R.sup.2 is: ##STR4## or R.sup.3 , or a combination thereof, and R.sup.3 is a C.sub.8 -C.sub.18 linear or branched alkyl chain; the interpolymer being prepared by polymerizing the monomers in a solvent system in which the monomers and interpolymer are soluble.